RIPK3 and neoplasm: For instance, IRF1 functions in both myeloid and epithelial cells to counteract AOM/DSS-induced colorectal tumorigenesis, while RIPK3 activation in colon cancer cells leads to increased cytokine expression in the tumor microenvironment, contributing to robust cytotoxic anti-tumor immunity (19, 22).